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MOLECULAR GENETIC APPROACHES TO DISEASES OF NEURAL 
DEVELOPMENT. 
Mohamad Bydon, Kaya Bilguvar, Fatih Bayrakli, Luis Kolb, and Murat Gunel.  
Department of Neurosurgery, Yale University School of Medicine, New Haven, CT. 
 
This study utilized novel genetic techniques in order to find causative gene mutations that 
underlie diseases of neural development.  Our laboratory has collected 175 cases of 
malformations of cortical development (MCD) from the United States and Europe.  Four 
of these cases are the focus of this manuscript:  two familial cases of infantile 
neuroaxonal dystrophy (INAD), a familial case of hereditary spastic paraparesis (HSP), 
and a sporadic case of Greig cephalopolysyndactyly (GCPS) and cerebral cavernous 
malformations (CCMs).   
 
The techniques utilized to study the affected patients include microarray-based single 
nucleotide polymorphism (SNP) genotyping and copy number variation (CNV) analysis, 
both of which are powerful tools in the hunt for disease-causing gene mutations.   
 
In the familial cases of INAD, we report two novel mutations in the PLA2G6 gene, 
previously shown to cause INAD when mutated.  In the familial case of HSP, we 
demonstrate linkage to the SPG11 locus on chromosome 15q.  Finally, in the sporadic 
 
case of GCPS and CCM, we published the first report on this novel syndrome along with 
a genetic analysis that demonstrates a microdeletion on chromosome 7p, resulting in 
heterozygous loss of both the GLI3 and CCM2 genes.   
 
The three studies presented in this manuscript demonstrate the utility of SNP genotyping 
and CNV analysis in revealing the genetic mutations that underlie diseases of neural 
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While humans share 99% of their DNA sequences, there are many examples of genetic 
variation in the genome, ranging from large chromosomal abnormalities to insertions or 
deletions of one or more nucleotides.  It is believed that within the 3 billion bases of the 
human genome, there are more than 10 million common nucleotide variations between 
individuals (1).  A single nucleotide variation occurs when a nucleotide – A, C, T, or G – 
in an individual’s DNA is altered.  For this variation to be considered a single nucleotide 
polymorphism (SNP), it must occur in 1% of the population.  The International 
Haplotype Mapping Project (2) has identified more than 2 million SNP markers, which 
can be used in large-scale genotyping.   
 
SNPs, as well as other genetic variations, have become of great interest to the scientific 
community because they are thought to predispose individuals to disease (3, 4).  
Advances in SNP genotyping have been made possible by the development of 
microarrays, membranes or glass slides on which probes – sequences of DNA – are fixed 
in an orderly arrangement.  Microarrays facilitate the detection of thousands of genomic 
variants, including SNPs and more recently copy number variations, in a sample 
simultaneously.  Microarray-based methods for SNP genotyping (5) have been used in 
linkage and association studies of complex disorders such as prostate cancer (6), 
rheumatoid arthritis (7), erythrokeratodermia variabilis (8), bladder cancer (9), systemic 
lupus erythematosus (10), and dyslipidemia (11) (Table 3). 
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In addition to their utilization in SNP genotyping, microarray-based methods have been 
used in the analysis of copy number variations (CNVs) spanning large chromosomal 
regions (12).  Sebat et al. (13) recently demonstrated the presence of CNVs, DNA 
segments found throughout the human genome in varying numbers among individuals 
because of deletions, insertions, or duplications.  These CNVs are common in apparently 
normal persons, but may also predispose toward or cause disease phenotypes (14).  
Advances in molecular genetic techniques now allow CNV analysis using a variety of 
microarray-based approaches including comparative genome hybridization (aCGH).   
 
In recent years, SNP genotyping and CNV analysis have been utilized to identify gene 
mutations responsible for malformations of cortical development.  Our laboratory is 
involved in ongoing efforts to uncover the genetic basis of disorders of cell proliferation, 
neuronal migration, and cortical organization, as well as other syndromes of neural 
development.  Through national and international collaborations, our laboratory has 
identified and collected DNA samples from patients and families afflicted with diseases 
of neural development.  Using both sporadic and familial cases, we have successfully 
employed array-based SNP and CNV approaches to uncover several disease-causing 
genetic mutations.   
 
In Bayrakli et al. (15), our laboratory reported the case of a Turkish family in which 6 
members were afflicted with autosomal recessive Parkinsonism.  First, whole-genome 
linkage analysis was performed using a microarray system that contains 56,860 SNP 
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markers.  The results of this initial genotyping demonstrated linkage to chromosome 
6q26, the region housing the parkin gene (PARK2) (Figure 1).  Mutations in PARK2 have 
been shown to be associated with early-onset Parkinson’s disease (16).  Array-based 
comparative genome hybridization (aCGH) was then performed to determine the 
presence of copy number variations (CNVs) in the DNA of an affected patient relative to 
pooled human genomic DNA controls.  The aCGH results revealed a homozygous 
microdeletion in the same region of chromosome 6q26 (Figure 2).  PCR amplification 
within the predicted deleted region in 3 affected siblings and two unaffected relatives 
confirmed the presence of a homozygous microdeletion in exon 5 of the PARK2 gene 
(Figure 3).   
 
The Bayrakli et al. (15) study demonstrates the utility of molecular genetic techniques in 
identifying disease-causing gene mutations.  Microarray-based SNP genotyping provided 
evidence of linkage to chromosome 6q26.  Comparative genome hybridization or CNV 
analysis reaffirmed this locus as the region of interest and demonstrated a microdeletion 
in the parkin gene.  Finally, PCR amplification confirmed the presence of a homozygous 
deletion in 3 affected siblings.   
 
Molecular genetic techniques, including SNP genotyping and CNV analysis, have been 
utilized by several research groups, including ours, to investigate the gene mutations that 
underlie malformations of cortical development.  These diseases and the genetic 
breakthroughs associated with them will be the focus of this manuscript.     
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Malformations of Cortical Development 
 
Advances in molecular genetics have led to the elucidation of causative genes behind 
several human brain diseases.  This has occurred concurrently with improved 
radiographic methods used to diagnose these disorders.  Prior to 1980, malformations of 
cortical development (MCD) were studied by pathologists at autopsy.  The advent of 
magnetic resonance imaging (MRI) allowed for earlier detection of these diseases.  For 
the first time, phenotypic descriptions could be matched to radiologic findings.  Interest 
in MCD has grown since then as the disorders have become increasingly recognized as 
significant causes of epilepsy, developmental delay, and other neurologic ailments.   
 
Several proposed classification schemes have attempted to organize MCD based on our 
growing understanding of brain development.  In 1996, Barkovich et al. (17) published a 
classification system that divided neural developmental pathology into disorders of cell 
proliferation, neuronal migration, or cortical organization.  These 3 events—proliferation, 
migration, and organization—define embryonic cortical development.  In the initial 
phase, neurons and glial cells proliferate in the ventricular and subventricular zones, 
respectively.  Following the start of proliferation, postmitotic neurons migrate to the 
cortical plate.  Finally, within the cortex, neurons undergo a process of vertical and 
horizontal organization as well as elaboration of their axonal and dendritic branches (18, 
19).   
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MCD can result from abnormalities in any of the 3 stages of cortical development.  In the 
initial classification (17), if a disease process involved more than one of the 3 stages, then 
it was classified based on the first abnormal step.  Additionally, the classification 
separated diffuse and focal malformations because they were thought to have separate 
pathophysiology.  The classification was revised in 2001 (20) and then again in 2005 (21) 
(Figure 1).  In their most recent effort, the authors hoped to account for the rapid 
accumulation of new information regarding the genetic basis of many diseases of neural 
development.  While the latest classification retains the 3 major groups of disorders 
described previously, it incorporates new information on the gene mutations that cause 
diseases of neural development (Figure 2).   
 
The increased focus on the genetic basis of MCD allows for less reliance on the 
phenotypic characteristics of these disorders.  A gene-oriented classification is necessary 
because mutations in different genes may result in the same phenotype, while various 
mutations in one gene may result in different phenotypes (21).  Many of the genetic 
breakthroughs on MCD have occurred recently using novel molecular genetic approaches 
(Figure 2).  These approaches have been utilized by several research groups, including 
ours, in order to uncover the genetic basis of disorders of cell proliferation, neuronal 
migration, and cortical organization, as well as the malformations of cortical 





Disorders of Cell Proliferation 
 
Diseases in this group may be due to abnormal proliferation or apoptosis, resulting in an 
increase or decrease in the number of neurons or glial cells, or both (20).  When the 
proliferation or apoptosis is diffuse, it leads to an abnormality in brain size, otherwise 
known as microcephaly or macrocephaly.  Three main types of microcephalies occur: 
microcephaly with normal to thin cortex, extreme microcephaly with thick cortex 
(microlissencephaly), or microcephaly with extreme polymicrogyria (21).  On the other 
hand, localized proliferation causes abnormal cell growth without a change in brain size.  
This set of disorders includes cortical hamartomas of tuberous sclerosis; cortical 
dysplasia associated with epilepsy; hemimegalencephaly (enlargement of one hemisphere 
leading to mental retardation and epilepsy); and neoplasms such as ganglioglioma, 
gangliocytoma, or dysembryoplastic neuroepithelial tumor. 
 
Recent studies have identified several gene mutations associated with disorders of cell 
proliferation.  Several genes have been shown to cause autosomal recessive 
microcephaly, including MCPH1 on chromosome 8p23 (22), ASPM on 1q31 (23, 24), 
CDK5RAP2 on 9q34 (25), CENPJ on 13q12.2 (25), and SLC25A19 on 17q25.3 (26).  
The ATR gene on 3q22-24 has been found to cause Seckel syndrome or 
microlissencephaly with short stature (24), while TSC1 (27, 28) and TSC2 (29, 30) on 
9q32 and 16p13.3 were shown to cause cortical hamartomas of tuberous sclerosis.   
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These findings illustrate that various gene mutations may lead to similar phenotypes.  
Such investigations contribute significantly to our understanding of disorders of cell 
proliferation.  Our laboratory has collected 13 familial or sporadic cases of disorders in 
this category including cortical dysplasia, microcephaly, and dysembryoplastic 
neuroepithelial tumor (DNET), as well as syndromes like infantile neuroaxonal dystrophy 
(INAD).  We collected two familial cases of INAD and our genetic studies revealed two 
novel mutations in the PLA2G6 gene, previously shown to be mutated in INAD.  These 
results will be discussed at length in this manuscript.   
      
 
Disorders of Neuronal Migration 
 
These diseases, resulting from abnormal migration of neurons from the ventricular zone 
to the cerebral cortex, often present on MRI as gray matter in the subependymal or 
subcortical regions (20).  Malformations within this group include lissencephaly, 
cobblestone complex, and heterotopia (21).  Lissencephaly or “smooth brain” is 
characterized by a lack of gyri, abnormally thick cortex, and enlarged ventricles.  
Subcortical band heterotopia (SBH) consists of a subcortical band of gray matter 
separated from the cortex by a band of white matter.  Both diseases comprise the so-
called agyria-pachygyria-band spectrum.  Cobblestone complex refers to a “cobblestone” 
cortex, abnormal white matter, large ventricles, and small brainstem and cerebellum (20).  
It is associated with congenital muscular dystrophy syndromes (37).  Finally, heterotopia 
have various forms, ranging from periventricular to subcortical to marginal glioneuronal.   
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Periventricular nodular heterotopia consist of small masses of gray matter that line the 
ventricular walls and protrude into the lumen (38).  Subcortical heterotopia (other than 
band heterotopia, described above) are less common than periventricular heterotopia.  
Depending on their size and location, subcortical heterotopia may result in developmental 
delay or mental retardation, hemiplegia, or epilepsy (20). 
 
Several genes have been implicated in disorders of neuronal migration.  Several groups 
have published gene mutations that underlie lissencephaly and subcortical band 
heterotopia, including the DCX gene on Xq22.3-23 (39-41), ARX on Xp22.13 (42, 43), 
LIS1 on 17p13.3 (44-46), RELN on 7q22 (47).  Mutations in the LARGE gene on 
22q12.3-13.1 (48), POMT1 on 9q34.1 (49), FKRP on 19q13.3 (50, 51), and FCMD on 
9q31 (52) have been shown to cause various syndromes within the cobblestone complex, 
while ARFGEF2 on 20q13.3 (53) and FLNA on Xq28 (54) are believed to mutated in 
bilateral periventricular nodular heterotopia. 
 
In this category, our laboratory has collected 42 cases of disorders, including heterotopia, 
periventricular development anomalies, and lissencephaly, as well as syndromes like 
hereditary spastic paraplegia (HSP).  For this latter syndrome, we have uncovered novel 
genetic findings based on a familial case of HSP.  Specifically, we were able to 
demonstrate linkage of our kindred to the SPG11 locus on chromosome 15q.  While 
SPG11 has been reported previously to be associated with cases of HSP, our results 
confirm and narrow the locus.        
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Disorders of Cortical Organization 
 
Diseases in this category occur when neurons reach the cortex, but fail to form normal 
cortical layers or connections.  They typically have abnormal gyri with normal cortical 
thickness (20).  Common disorders include polymicrogyria (many small gyri separated by 
shallow sulci), schizencephaly (polymicrogyria with clefts), cortical dysplasia without 
balloon cells, and microdysgenesis (21).  As with other MCD, these diseases typically 
present with developmental delay, cognitive deficits, and epilepsy.   
 
Much work remains to be done on the genetic basis of the disorders of cortical 
organization.  The only significant gene mutation identified has been that of GPR56 on 
16q13 in bilateral frontoparietal polymicrogyria (67).  Our laboratory has collected 55 
cases of disorders in this category that includes cortical developmental anomalies, 
polymicrogyria, and schizencephaly.  These cases will allow us to shed us light on the 
genetic variations that cause disorders of cortical organization.  Recently, we published 
the case of a patient with a disorder of cortical organization, Greig 
cephalopolysyndactyly (GCPS), and cerebral cavernous malformations (CCM).  Our 
genetic studies uncovered a microdeletion in chromosome 7p, which resulted in the loss 
of the GLI3 and CCM2 genes.  While deletions in these two genes have been previously 
shown to cause GCPS and CCM respectively, this is the first case in the literature of a 
patient with deletions in both genes and the hallmarks of both diseases.  To our 
knowledge, the combination of GCPS and CCM represents a novel genetic syndrome, 
one that will be discussed further in this manuscript.           
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Malformations of Cortical Development, Not Otherwise Classified 
 
This fourth category includes disorders that cannot be easily placed into the 3 
aforementioned groups, including metabolic disorders, peroxisomal disorders, and 
unclassified syndromes.  We have collected 65 patients with various syndromes of neural 
development, ranging from autism to childhood epilepsy.   
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STATEMENT OF PURPOSE & SPECIFIC AIMS 
 
The purpose of this study is to utilize molecular genetic techniques, specifically SNP 
genotyping and CNV analysis, in order to find genetic mutations that cause diseases of 
neural development.  This manuscript details our studies on three diseases in particular:  
INAD, HSP, and GCPS.  Our aim is to uncover the gene mutations that cause these 
disorders so that we may develop a better understanding of the pathophysiology of these 








Patient Identification and Collection of Blood Samples 
 
The author of this manuscript attained approval for this study from the Yale Human 
Investigations Committee (Protocol 7680).  The patients afflicted with MCD were 
identified by physicians at Yale New Haven Hospital as well as collaborators at other 
institutions in the United States and Europe.  For patients identified at Yale New Haven 
Hospital, the author attained consent and collected their blood samples.  For patient 
identified elsewhere, consent was attained and blood samples were collected by the 
collaborating physicians.   
 
 
Isolation of Genomic DNA 
 
Total genomic DNA was isolated from lymphocyte nuclei using a procedure described by 
Bell et al. (75).  Ten milliliters of blood collected in a heparinized tube and then kept at 
4°C was mixed with 90 ml of 0.32 M sucrose / 10 mM TrisHCl (pH 7.5) / 5 mM MgCl2 / 
1% Triton X-100 at 4°C to lyse all cells.  The nuclei were collected by centrifugation at 
1000 X g for 10 min.  The nuclear pellet was suspended in 4.5 ml of 0.075 M NaCl / 
0.024 M EDTA (pH 8.0) with a Pasteur pipette.  Then 0.5 ml of 5% sodium dodecyl 
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sulfate and proteinase K at 2 mg/ml were added and the mixture was incubated for 
approximately 12 hr at 37°C.   
 
The digest was gently mixed with 5 ml of phenol saturated with 20 mM Tris HCl (pH 
8.0).  Five milliliters of chloroform / isoamyl alcohol (24:1, vol/vol) was added and 
gentle mixing was continued.  The phases were separated by centrifugation for 15 min at 
1000 X g.  The upper, aqueous, phase was removed and gently extracted with the 
chloroform / isoamyl alcohol mixture.  After centrifugation, the aqueous phase was 
removed; 0.5 ml of 3 M sodium acetate and 11 ml of 100% ethanol (at room temperature) 
were added.  The DNA was precipitated by inverting the tube several times and then 
removed with a Pasteur pipette and placed in 1 ml of 10 mM Tris HCl (pH 7.5) / 1 mM 
EDTA.  The DNA was allowed to dissolve at 4°C.  From 10 ml of blood, 20-50 μg of 
DNA was obtained.  In cases where the yield is low, we incubate the DNA at -20°C in 
the presence of ammonium acetate. Genomic DNA was isolated by the author and 
laboratory technicians.     
 
 
Single Nucleotide Polymorphism Genotyping 
 
Genotyping was performed using the GeneChip Mapping 50K XbaI Array (Affymetrix 
Inc., Santa Clara, CA) containing 56,860 single nucleotide polymorphism (SNP) markers 
for genome-wide linkage analysis, according to the company’s protocols.  Briefly, after 
DNA was digested with XbaI, adapters were ligated to the product.  Primers were then 
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used to amplify the product by PCR.  Following purification, fragmentation, and labeling, 
biotin-labeled DNA product was hybridized to the Array chip.  Arrays were then washed, 
stained, and scanned (76).  Affymetrix Micro-Array Suite 5.0 software was utilized to 
obtain raw microarray feature intensities, the results of which were processed to derive 
SNP genotypes using the Affymetrix Genotyping Tools software package.  SNP 
genotyping was performed by laboratory technicians.  
 
 
Genechip Data Analysis 
 
The Genome Analysis programs provided by Affymetrix were used for basic analysis of 
the Genechip data.  Multipoint linkage analysis was performed using a UNIX-based 
program (Chunky).  This program, initially described by Nahed et al. (76), parses the data 
into individual files that convey chromosome number, SNP markers, map distances, 
genotype calls, and allele frequencies.  Final linkage analysis was then performed using 
Allegro software (DeCode Genetics, Inc) (77).  We assumed an autosomal recessive 
inheritance pattern and assigned a 70% to 99% penetrance and a phenocopy rate of 0.001.  
Allele frequencies for the GeneChip SNPs were obtained from Affymetrix.  Genechip 






Confirmation of Linkage Using Microsatellite Short Tandem Repeat Markers 
 
Microsatellite short tandem repeat (STR) markers are used in order to fine map the 
linkage interval.  Genomic regions with LOD scores approaching the theoretical 
maximum were further characterized and verified using STR markers within said regions 
according to the physical map data from the University of California at Santa Cruz 
(UCSC) Genome Browser (http://genome.ucsc.edu/index.html?org=Human).  All 
available members of the family, both affected and unaffected, were genotyped.  This 
strategy is often referred to as a 2-stage design in linkage analysis (78).  All genotyping 
for microsatellite analysis was performed using PCR, with detection of fluorescent 
products on an ABI 3700 sequencer equipped with the Genescan and Genotyper software 
(ABI, Norwalk, CT).  The author was involved in choosing the STR markers utilized in 
the confirmation of linkage.  The PCR was performed by laboratory personnel.  
 
 
Candidate Gene Mutational Analysis 
 
Exon-intron boundaries of the candidate genes SPATA5L1 and SEMA6D within the 
linked interval were determined based on the University of California at Santa Cruz 
(UCSC) Genome Browser (NCBI Build 36.1).  PCR primers were designed using 
PRIMER3 (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi).  Exon amplicons 
were amplified and sequenced using standard techniques.  Mutational analysis was 
performed by the author and by laboratory personnel.   
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Array CGH for Copy Number Variant Analysis 
Isolated DNA from the patients was submitted for whole genome and chromosome-
specific aCGH analysis by high-resolution, tiled microarray (NimbleGen Systems, 
Madison, WI) to determine copy number variations (CNVs).  These arrays employ 
385,000 probes spanning all non-repetitive regions of the human genome on a single 
chip, tiling the full genome at a median probe spacing of 6,000 bp.  The chromosome-
specific arrays contain 385,000 oligomeric probes of lengths between 45–85mers with a 
median probe spacing of 10 bp.  Patient DNA was cohybridized with pooled control 
DNA to determine copy number differences (deletions or amplifications) across the entire 
genome.  Array CGH was performed by laboratory personnel. 
 
 
Array CGH Data Analysis 
 
All arrays were scanned with a GenePix 4000B Scanner (Molecular Devices Corporation, 
Sunnyvale, California) and normalized using QSPLINE (79) within the NimbleScan 
software package (Nimblegen Inc., Madison, WI).  The normalized intensities were 
subsequently analyzed with the Circular Binary Segmentation (CBS) algorithm (80) to 
determine the significant breakpoints in log2 intensities along the chromosomes.  Using 
average window sizes of 1X, 5X, 10X, and 20X (X=the median inter-probe distance), we 
determined the possible segments of the genome that were different between our patients 
and pooled, population-matched control samples.  A segment (y) was considered to be 
significant if y > 0.3 or y < -0.3.   
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The normalized intensities were also analyzed with our Seed algorithm (Mason et al., in 
preparation), which creates windowed 5-probe averages along the genome after removing 
outlier data points (Dixon test) to detect additional small CNVs occasionally missed by 
CBS.  Two patients with large-scale, known duplications in their genome were used to 
empirically determine a threshold for the Seed algorithm that kept sensitivity above 90% 
and specificity above 99.99%.  We considered segment (y) to be significant in Seed if y > 






Array CGH analysis results were confirmed with quantitative RT-PCR using the standard 
curve method for absolute quantitation.  Primers were designed using Primer Express 
Software, version 2.0 (Applied Biosystems), with the following criteria: amplicon size of 
80 to 200/250 bp, GC content of 20 to 80%, no more than two guanines or cytosines in 
the primer 3’ end, and melting temperature (Tm) of 59 to 60°C.  Finally, the Basic Local 
Alignment Search Tool (http://www.ncbi.nlm.nih.gov/blast/) was used for these primers. 
 
The experimental design and calculations were performed as described by Applied 
Biosystems (User Bulletin #2).  To determine copy number changes, fourfold ranges of 
five different serial dilutions from five pooled normal control DNA samples were used.  
 18
In addition, we used 5 ng of genomic DNA from the patient’s DNA and pooled normal 
control DNA.  The RT-PCRs were performed in triplicate for each reaction.  The 15-μl 
reactions contained 1X final concentration of Power SYBR Green PCR Master Mix (part 
number 4367660, Applied Biosystems) and 400 nM of each primer (Invitrogen).  Each 
experiment was performed using a 384-well optical PCR plate and the Applied 
Biosystems machine (model 7900HT) with default cycling conditions. 
 
A standard curve was created using the calculated threshold cycle of each dilution for 
each gene.  Amplifications were performed on the same diluted samples using primers for 
the reference and target genes.  For all experimental samples, the target quantity was 
determined from the standard curve and divided by the target quantity of the normal 
reference DNA.  To assess reaction specificity and to verify product identity, melting 
curve analysis was performed following amplification.  We used the standard curves with 
an efficiency between 90% and 100%, which corresponds to a slope between 23.58 and 











Our laboratory has collected 175 cases of malformations of cortical development (MCD), 
including 13 cases of disorders of cell proliferation, 42 cases of disorders of neuronal 
migration, 55 cases of disorders of cortical organization, and 65 cases of MCD not 




We are currently in the process of performing chip analysis on our samples (results not 
shown) in order to find the rate of homozygous deletions, heterozygous deletions, and 
amplifications relative to controls.        
 
 
Disorders of Cell Proliferation 
 
As stated earlier, our laboratory has collected 13 cases of disorders in this category,  
including 3 cases of cortical dysplasia, 1 case of microcephaly, 8 cases of 
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dysembryoplastic neuroepithelial tumor (DNET) as well as one familial case of infantile 
neuroaxonal dystrophy (presented below).              
 




Infantile neuroaxonal dystrophy (INAD) is an autosomal recessive neurodegenerative 
disorder characterized by progressive motor and mental deterioration beginning in the 
first or second year of life.  Clinically, the disease includes bilateral pyramidal tract signs, 
truncal hypotonia, and late-course spastic tetraplegia, blindness, and dementia (31).  
Death usually occurs before the age of 10 years.    
 
While the pathophysiology of INAD has not been definitively elucidated, it is believed 
that defects in axonal transport (32) or synaptic transmission (33) lead to the histologic 
findings of axonal swelling and “spheroid bodies” in the central and peripheral nervous 
system.       
 
MRI scanning of INAD patients has occasionally revealed iron accumulation in the 
globus pallidus, leading some to hypothesize that a disturbance in iron protein function 
plays an important role in the pathogenesis of this disease (34).  
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Recently, two studies have implicated mutations in PLA2G6, a gene encoding calcium-
independent phospholipase A2, as being associated with INAD.  In the first study, 
Morgan et al. identified 44 unique mutations in PLA2G6 in patients affected with INAD 
and neurodegeneration with brain iron accumulation (NBIA) (35).  In the second study, 
Khateeb et al. reported the identification of a unique PLA2G6 mutation associated with 
INAD in two Israeli Bedouin families (36).  Our laboratory collected two Turkish 




Our laboratory collected two sporadic cases of INAD (Figure 5).  In the first case, the 
affected children, DY, presented at the age of 2 years old with complaints of loss of 
ability to walk or speak and with foot abnormalities.  DY also displayed signs of truncal 
hypotonia, manifested by an inability to sit up straight without support.  DY was 
delivered at term in a normal spontaneous vaginal delivery.  At six months, she was able 
to crawl and sit without support.  She was normal until the age of 2 years, when she 
began deteriorating.  At 3 years old, skin biopsy was performed, revealing distended 
demyelinated nerves around sweat glands and blood vessels.  The axons contained 
granular, electron-dense material with occasional clefts, a histopathological finding 
consistent with infantile neuroaxonal dystrophy.  This patient’s sibling also had INAD 
and died at the age of 7 years.  Neither parent is affected with the disease, consistent with 
an autosomal recessive trait.  
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The second affected child, MM, presented at the age of 1.5 years with complaints of 
losing ability to walk or speak.  By the age of 1 year, the patient had been able to walk 
and speak words.  A few months later, the patient presented with deterioration of both 
faculties. Skin biopsy revealed findings of distended axons with granular, electron dense 
material, consistent with INAD.  No other members of this family have been affected 
with INAD.      
 
The MRI scans on both patients showed no evidence of hypointensity in the globus 
pallidus, indicating a lack of iron accumulation.  Both scans demonstrated signs of 
cerebellar atrophy on T2 weighted MRI as well a mild periventricular hyperintensity on 




Direct PLA2G6 sequencing using the DNA of the two affected children revealed two 
novel mutations in exons 12 and 15 of the gene.  Both mutations were single nucleotide 
substitutions.  In exon 12, an A → G mutation resulted in a substitution of arginine with 







Disorders of Neuronal Migration 
 
Our laboratory has collected 42 familial and sporadic cases of disorders in this category.  
These include 5 cases of heterotopia, 3 cases of periventricular developmental anomalies, 
24 cases of lissencephaly, and a familial case of hereditary spastic paraplegia (presented 
below).    
 




Hereditary spastic paraplegias (HSP), also known as familial spastic paraparesis (FSP), 
are a genetically and clinically heterogeneous group of neurological disorders 
characterized by progressive lower extremity spasticity.  HSPs can be associated with 
other neurological sequelae including neuropathy, retinopathy, dementia, icthyosis, 
mental retardation, deafness and seizures (“complicated” form), or by upper motor 
neuron findings including lower-extremity spasticity and neurogenic bladder alone 
(“uncomplicated” form).  The diagnosis is confirmed through neurological testing, 
muscle biopsy, EMG, MRI, and detailed genetic history.  The majority of HSP familial 
forms reported to date, up to 80%, demonstrate autosomal dominant patterns of 
expression, while the remainder demonstrate autosomal recessive and X-linked recessive 
inheritance patterns (55-57).  
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The first association of HSP with mental retardation and epilepsy, designated “SPERM” 
(OMIM 182610), was reported as a novel genetic disorder with an autosomal dominant 
pattern of inheritance (58).  The family described was excluded from 8 previously 
described autosomal dominant HSP loci by linkage (59).  Other families with 
complicated forms of HSP have been reported including an autosomal recessive form 
with a relatively constant clinical presentation of pyramidal tract signs in the lower 
extremities which progress to the upper extremities, gradual cognitive impairment, an 
onset before age 20, and radiographic findings of thinning of the corpus callosum (CC) 
and cortical atrophy known as HSP-TCC, or SPG11 (OMIM 604360) (60-66).  Our 
laboratory is preparing a manuscript describing a new family from Eastern Turkey with 
autosomal recessive HSP associated with early-onset mental retardation, epilepsy and a 
variably thinned corpus callosum on MRI demonstrating linkage to the SPG11 locus at 
15q13-15 using both SNP genotyping and CNV analysis.  This data, when added to those 





The family was identified in Southeastern Turkey after the index case, a product of a 
consanguineous marriage, presented to medical attention with spastic paraparesis, mental 
retardation, and epilepsy.  Clinical testing included magnetic resonance imaging (MRI), 
electromyography (EMG), electroencephalogram (EEG), cerebrospinal fluid analysis, 
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and other specific laboratory examinations such as routine blood work, blood thyroid 
hormone, ammonium, lactate levels, urine analysis. 
 
Parents of the affected children were normal and consanguineous, providing evidence for 
an autosomal recessive inheritance pattern.  Affected status was assigned after clinical 
documentation of prominent lower followed by upper extremity paraparesis with long 
(pyramidal) tract signs (spasticity, hyperreflexia, and bilateral Babinski sign), and 
epileptic discharges on electroencephalogram (EEG) (Figure 8). 
 
Case 1 (V-1) 
 
The index case was a four year-old female, a product of a consanguineous marriage, who 
presented with neurological decline.  The patient was neurologically normal until the age 
of 6 months when parents became concerned with the child’s lack of interactivity.  By the 
age of 9 months, the child developed seizures which were controlled medically.  On 
neurologic examination, the patient demonstrated motor and mental retardation, spasticity 
in the lower limbs, hyperreflexia, and an inability to sit without support.  An MRI 
revealed a thinned corpus callosum on coronal T2 and sagittal T1 imaging (Figure 9). 
 
Case 2 (V-2) 
 
The second affected was the brother of the index case, a twelve year-old male.  The 
patient developed normally but, as with Case 1, began having seizures at 10 months of 
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age.  He also suffered from mental retardation, spasticity in lower and upper limbs, 




The third affected individual was a first cousin of the index case, also a product of a 
consanguineous marriage.  This ten-year-old boy presented with seizures and mental 
retardation at age 6 months.  He had difficulty swallowing solid food.  Neurological 
examination revealed mental retardation, spasticity in the lower limbs, hyperreflexia, and 
inability to sit without support. MRI revealed mild, diffuse atrophy of grey and white 
matter with a thinned corpus callosum (Figure 9). 
 
In all 3 patients, EEG studies showed myoclonic generalized epileptic discharges.  
Laboratory values provided no evidence for a lysosomal, mitochondrial, or peroxisomal 
disorder or a disturbance of amino acid or organic acid metabolism.  CSF analysis was 
unremarkable. 
 
Single Nucleotide Polymorphism Genotyping 
 
We performed array-based genotyping on all available affected individuals and their 
parents (n=7).  The 50K SNP arrays provide estimated information with a mean marker 
distance of 26 kb with an average of 53,970 genotypes scored per subject (SNP call-rates 
ranged between 92%–97%).  Multipoint linkage analysis demonstrated a mean LOD 
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score of > 3 (maximum: 3.6287) within a 9.8 cM region between markers rs10518676 
and rs2129773 on chromosome 15q15-q21 (Figures 10 and 11). 
 
Linkage Using Microsatellite Short Tandem Repeat Markers 
 
The linkage interval was verified and confirmed using seven highly polymorphic di and 
tetranucleotide microsatellite repeats across our linkage interval.  As expected, the 
parents were heterozygous for the affected haplotype while the children with the HSP-




Screening of the candidate genes within the linkage interval, SPATA5L1 and SEMA6D 
failed to reveal any polymorphisms that segregated with the phenotype (data not shown). 
 
Array CGH for Copy Number Analysis 
 
Whole genome aCGH and chromosome 15-specific aCGH identified several copy 
number variations throughout the genome.  None of these variations, however, were 





Disorders of Cortical Organization 
 
Our laboratory has collected 55 familial and sporadic cases of these disorders, including 
20 cortical developmental anomalies, 19 cases of polymicrogyria, 8 cases of 
schizencephaly, and one case of Greig cephalopolysyndactyly and cerebral cavernous 
malformations (presented below).     
 




Greig cephalopolysyndactyly (GCPS) is a syndrome characterized by polydactyly, 
macrocephaly, and hypertelorism.  Patients with severe GCPS can also present with 
mental retardation, seizures, and hydrocephalus.  Mutations in GLI3 at the chromosome 
7p14 locus have been shown to cause GCPS (68). 
 
Cerebral cavernous malformations (CCM) are abnormally dilated vascular channels, 
lined by a single layer of endothelium, that are prone to leakage resulting in cerebral 
hemorrhage.  When symptomatic, the clinical manifestations can include headache, 
seizure, and neurological deficits.  The heritability of CCM has been well established, 
and both familial and sporadic forms have been described.  To date, three genes when 
mutated have been shown to cause CCM: CCM1 on chromosome 7q21 (KRIT1) (69), 
CCM2 on 7p13 (Malcavernin) (70, 71), and CCM3 on 3q26 (PDCD10) (72, 73).  
 29
 
Our group reported the case of a patient who presented with a novel syndrome combining 
the clinical hallmarks of CCM and GCPS (74).  High resolution CNV analysis, or 
comparative genome hybridization (aCGH), was used to identify the causal deletion on 





This 32-month-old girl presented to Yale University with a history of developmental 
delay.  The mother’s pregnancy and delivery were uncomplicated, and the child was born 
vaginally at a gestational age of 40 weeks (APGAR scores: 8 at 1 minute and 9 at 5 
minutes).  The family had no history of mental retardation, infant deaths, or multiple 
spontaneous abortions.  The patient has two older siblings who were noted to be 
developmentally normal and without medical problems.   
 
On examination the patient exhibited hypotonia with dysmorphic facial features, bilateral 
polysyndactyly of the great toes (Figure 6), proptosis of the left eye, and a wide-based 
stance.  Her height and weight were in the 25th percentile, whereas her head 
circumference was in the 90th percentile.  She had a prominent forehead, synophrys, mild 
thoracolumbar kyphosis, and a noncommunicating sacral dimple.  Her neurological 
examination was nonfocal.   
 
 30
The facial features, hypotonia, and developmental delay indicated the possibility of a 
genetic syndrome involving polydactyly.  To rule out chromosomal abnormalities, G-
banded karyotyping was performed and was found to be normal (46, XX).  The x-ray 
film studies confirmed bilateral polydactyly and showed normal hands and a kyphotic 
spine (Figure 6). 
 
At age 4, seizures developed and the patient underwent additional neurological 
examination and brain imaging, which revealed the presence of multiple CCMs.  The 
child was referred to the Yale Neurovascular Center.  Axial T1-weighted MR imaging 
demonstrated multiple CCMs in the periventricular region as well as the subcortical 
parietal and frontal lobes (Figure 6).  On detailed examination, we noted mild gyral 
abnormalities consisting of possible asymmetry of the central sulci (Figure 6). 
 
Array CGH for Copy Number Analysis 
 
Given the current overlap in clinical features between CCM and GCPS, the known 
involvement of GLI3 on chromosome 7p in the latter syndrome, the recent identification 
of causal deletions of CCM2 in some patients with CCM (71), and a normal G-banded 
karyotype in this patient, we elected to utilize array CGH to search for CNVs leading to 
this clinical picture.  Array CGH revealed no CNVs in the regions of CCM1 or CCM3 
(Figure 7).  However, a possible deletion was detected at the CCM2 locus on 
chromosome 7p, consisting of 466 probes with an average log2 intensity of less than 
20.5, which exceeded the cutoff for statistical significance of 20.3.  The putative deletion 
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Quantitative PCR confirmed a heterozygous deletion encompassing the genes CCM2 and 
GLI3 (Figure 7) as well as several intervening genes, including HECWI, CAMK2B, and 
NPCL1 (Table 4).  The quantitative RT-PCR analysis also confirmed two normal copies 
of the genes centromeric (IGFBP1, TBRG4, ADCY1, and IGFBP3) and telomeric 






The results of the three studies presented above demonstrate the utility of SNP 
genotyping and CNV analysis in uncovering the genetic basis of MCD.  Specifically, 
three diseases are presented in this manuscript:  infantile neuroaxonal dystrophy, Greig 
cephalopolysyndactyly, and hereditary spastic paraparesis. 
 
In the familial case of infantile neuroaxonal dystrophy, our results are the third, after 
Morgan et al. and Khateeb et al., to implicate PLA2G6 as being associated with the 
disorder.  The two novel mutations presented in this study along with the mutations in 
Morgan et al. will prove useful clinically in the diagnosis of INAD, which currently relies 
on nonspecific histologic findings on invasive biopsy.  A recent paper in Seminars in 
Pediatric Neurology stated that once INAD is suspected, DNA testing should be utilized 
to confirm the diagnosis (81).  In the future, genetic testing for this disease may replace 
tissue biopsy, which can be avoided altogether except in cases where testing fails to 
demonstrate a PLA2G6 mutation.    
 
The affected individuals in the INAD study, unlike a number of the individuals in 
Morgan et al., did not have high iron concentrations in the basal ganglia.  The possibility 
exists that these represent two distinct disease processes:  INAD without brain iron and 
INAD with brain iron.  Nevertheless, PLA2G6 mutations have been shown, in this and in 
previous findings, to be associated with INAD regardless of brain iron concentration.   
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Calcium-independent phospholipase A2, the protein product of PLA2G6, is involved in 
cell membrane homeostatis, arachidonic acid release, and leukotriene / prostaglandin 
synthesis.  It has been hypothesized that a loss of function mutation in PLA2G6 and the 
subsequent defect in phospholipase A2 lead to excessive levels of membrane 
phosphatidylcholine, which may result in the axonal pathology observed in INAD (35).  
The specificity of this effect on the central and peripheral nervous systems raises the 
question of PLA2G6 expression patterns.  Currently, our laboratory is studying the 
expression of PLA2G6 in order to shed light on this issue. 
 
In the case of the patient with Greig cephalopolysyndactyly and cerebral cavernous 
malformations, our laboratory reported a seemingly new clinical syndrome resulting from 
a heterozygous deletion affecting chromosome 7p14-13.  Our results illustrate the utility 
of high-resolution array CGH in the study of suspected genetic syndromes.  We used this 
technique to investigate possible variations in the three established CCM loci (7p, 7q, and 
3q).  We found a statistically significant CNV on chromosome 7p, which was then 
confirmed on quantitative RT-PCR to be a deletion of the interval containing the genes 
CCM2 (causing CCMs) and GLI3 (causing GCPS).   
 
Greig cephalopolysyndactyly syndrome is characterized by polydactyly, hypertelorism, 
developmental delay, syndactyly, and macrocephaly.  Moreover, two additional 
syndromes with clinical features overlapping those of GCPS have been described.  
Acrocallosal syndrome, like GCPS, is characterized by polysyndactyly, macrocephaly, 
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and hypertelorism; however, patients with this syndrome also show dysgenesis of the 
corpus callosum (82) and tend to have more severe developmental delay than those with 
GCPS.  Pallister–Hall syndrome shares with GCPS the key features of postaxial 
polydactyly and developmental delay but does not include hypertelorism or 
macrocephaly (68).  The case reported by our laboratory is the first instance of GCPS 
associated with CCMs as part of a broader syndrome marked by a 7p14-13 deletion. 
 
In addition to CCM2 and GLI3, deletions on several other genes within the interval were 
confirmed on quantitative RT-PCR (Table 4).  However, bioinformatic analysis of 
sequence conservation of the brain-expressed genes within this region identified only 
GLI3 as having a strongly conserved element (83) or highly conserved element (84) 
across vertebrates.  This result suggests that these other transcripts within this interval 
may not be under strong stabilizing selection.  In conjunction with the absence of any 
additional clinical features beyond those attributable to CCM or GCPS in the affected 
patient, this analysis suggests that heterozygous deletions of these additional transcripts 
may be well tolerated. 
 
In the report on this patient, we characterized a novel syndrome consisting of CCMs, 
polydactyly, developmental delay, and hypertelorism resulting from a 7p14-13 deletion 
including the genes CCM2 and GLI3.  Our identification of the causative submicroscopic 
deletion, which was not identified using standard genetic testing methods, suggests that 
high resolution chromosomal analysis and neuroimaging studies are indicated when 
evaluating syndromic patients with neurological problems.   
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This manuscript also presents a familial case of hereditary spastic paraparesis.  In this 
investigation, a member of our laboratory identified a family from eastern Turkey with 
autosomal recessive HSP, epilepsy, mental retardation, and a thinned corpus callosum 
(TCC) on MRI demonstrating linkage to the SPG11 locus at 15q15.1-q21.3, a region 
between 38.1 - 51 Mb.  The clinical criteria for HSP-TCC are defined as normal motor 
development followed by a slowly progressive spastic paraparesis, mental retardation, 
and a very thin corpus callosum on imaging (64-66).  Other clinical signs that have been 
reported include extrapyramidal signs, hyperreflexia, dysphagia, dysarthria, amyotrophy, 
urinary incontinence, muscle atrophy, and peripheral neuropathy with cortical atrophy 
and white matter changes on imaging (60-63).  The average age of onset has been 
reported to be in the second decade (60). 
 
In HSP, significant phenotypic variability exists within affected members of families with 
respect to clinical signs and radiographic signs.  For example, some affected patients 
demonstrate various degrees of thinning of the corpus callosum on MRI, thought to 
represent a progressive finding of neuronal loss (60, 62, 63, 66).  The family reported 
here differs from those previously reported with respect to the uniformly early onset of 
disease (in the first year of life) including epileptic seizures and a mildly-thinned corpus 
callosum on MRI, further expanding the phenotype.  Interestingly, no cases of epilepsy 
were reported in any of the families demonstrating linkage to SPG11.  The only prior 
reported case of HSP with epilepsy was from the family with the so-called autosomal 
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dominant “SPERM” syndrome (58), though others have reported affected patients with 
seizures late in disease progression (85). 
 
Linkage analysis of the SPG11 locus for HSP was first reported by Martinez Murillo et 
al. (65) in 7 families from Italy and North America, between markers D15S1007 and 
D15S1012 on chromosome 15q13-15, a region of approximately 6.9 cM corresponding to 
5 Mb on chromosome 15 (Figure 13).  This linkage region was subsequently expanded 
(64) to between markers D15S971 and D15S117, a region of 26.7 cM corresponding to 
23 Mb in 10 Japanese families with HSP-TCC.  Originally described in the Japanese 
population (85-87), there have been several reports in the literature of families with HSP-
TCC from different ethnicities, with the majority of families appearing to originate from 
the Mediterranean region (60-63, 65).  Genetic linkage results in many of these families 
have confirmed or narrowed the SPG11 locus (60, 62, 63, 66).  A recently published 
paper by Olmez et al. (61) reported linkage in 4 Turkish families in a region between 
markers D15S968 and D15S132.  The authors argue that their results narrow the 
centromeric end of the region and, in effect, exclude the region defined by Martinez 
Murillo et al. (65).  Our linkage data confirm the results of Olmez et al. (61), also 
excluding the first reported interval (Figure 13). 
 
Chromosomal copy number alterations can lead to over activation or inactivation of 
genes in humans leading to cancer or disease phenotypes.  Comparative Genomic 
Hybridization (CGH) is a method to detect chromosomal copy number by comparing 
hybridization intensity of a patient’s DNA to a control DNA sample (88) and has become 
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an important tool in rapid identification of functional mutations within linkage intervals 
(89-91).  In the case of a family with HSP, we hypothesized that CNVs within the linkage 
interval might be causative of the disease phenotype.  We performed array-based whole-
genome and chromosome 15-specific CGH in the family.  Analysis of the array results 
did not show any CNV within the linkage interval in affected patients.  Furthermore, 
mutational analysis of the potential candidate genes SPATA5L1 and SEMA6D in this 
region did not reveal any causative mutations (60, 63). 
 
In addition to HSP, a second congenital neurological disorder demonstrates linkage to the 
same interval as SPG11.  Amyotrophic lateral sclerosis type 5 (ALS5) is characterized by 
gait disturbance, spasticity, mental retardation, and severe bulbar and pseudobulbar 
findings and demonstrates linkage between markers D15S146 and D15S123 (92).  It is 
possible that this phenotype is a part of the same spectrum of neurological disorders as 
HSP-TCC, caused by different mutations within the same gene (that ALS5 is an allelic 
disorder to HSP-TCC) supporting the idea that HSP-TCC represents a syndrome with 
broad phenotypic and genetic heterogeneity.  This hypothesis is plausible as it was 
previously demonstrated that ALS2 is allelic to infantile ascending hereditary spastic 
paralysis (IAHSP) (93).  More compelling is the fact that many families with autosomal 
recessive HSP-TCC (families with affected members fitting the clinical criteria of the 
syndrome) exclude by linkage the reported SPG11 locus (60, 62, 66).  This clearly argues 
in favor of genetic heterogeneity of the disorder. 
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Our results for HSP confirm previously published linkage analysis in families 
demonstrating linkage to the SPG11 locus on 15q and demonstrate the absence of CNV 
within the linkage interval in this family. The phenotype reported here adds to the broad 
spectrum of clinical findings within the HSP-TCC syndrome.  These results, when 
dovetailed with those previously published, demonstrate phenotypic heterogeneity of a 
common clinical entity with a common genetic cause.  The explanation of phenotypic 
variation within patients linking to the SPG11 locus is likely multifactorial and a 
combination of non-genetic, compound genetic, and mutation-specific causes. 
 
The three cases presented in this manuscript demonstrate the utility of molecular genetic 
approaches, particularly SNP genotyping and CNV analysis, in uncovering the genetic 
basis of neural developmental disease.  In the familial case of INAD, our laboratory was 
able to find two novel mutations in the PLA2G6 gene.  In the sporadic case of GCPS and 
CCM, CNV analysis using aCGH was used to identify the chromosome 7 deletion 
affecting the GLI3 and CCM2 genes.  These results establish this unique clinical 
presentation as a novel syndrome combining the hallmarks of GCPS and CCM.  Finally, 
in the case of the Turkish family with HSP, high density SNP genotyping was used for 
whole genome linkage analysis, allowing us to further narrow the previously established 
linkage interval for this autosomal recessive disease.  Although in this case we were not 
able to identify a causative gene mutation, narrowing the interval of the SPG11 locus on 
chromosome 15 will help guide future efforts to hunt the gene(s) responsible for HSP.   
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Our laboratory continues to perform mutational analysis on candidate genes in this locus 
as well as other regions associated with neurologic disorders.  The molecular genetic 
approaches described in this manuscript will further enhance our understanding of the 
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Figure 1: Parkinsonian family pedigree and linkage.  a: Family pedigree (colored 
shapes designate family members with Parkinsonism).  b: Linkage analysis using SNP 
microarrays demonstrates linkage with a LOD score of 5.08 (LOD > 3 represents 
significance) to a region of chromosome 6 housing the parkin gene.  Adapted from 

















Figure 2: Parkinsonian family copy number analysis.  a: Scatter plot of whole genome 
array-based comparative genome hybridization demonstrates a region within the linkage 
interval predicting a homozygous microdeletion.  Scattered points represent normalized 
log2 ratios (y) for probes along the chromosome.  A segment was considered to be 
significant if y > 0.3 or y < -0.3.  These results show a region with an average log2 ratio 
(y) of -1.16, suggesting a homozygous deletion.  b: Scatter plot of aCGH specific for 
chromosome 6 demonstrates a higher density of probes and prediction of homozygous 




Figure 3: Parkinsonian family PCR deletion.  a: PCR confirmation of the 
microdeletion.  The top image represents amplification using intronic primers 
immediately flanking exon 4, confirming the presence of this exon in all family members.  
The middle image demonstrates amplification using primers that flank exon 5, showing a 
microdeletion in 3 affected siblings.  b: This diagram illustrates the location of the 





Figure 4:  Images of malformations of cortical development.  The diseases presented 
in these image include corpus callosum hyperplasia, a disorder of cell proliferation (a); 
subcortical band heterotopia or “double cortex,” a disorder of neuronal migration (b); and 







Figure 5: Two sporadic cases of INAD.  In the first kindred, the dark circle represents a 
young child affected with INAD.  Her brother, who was also had INAD, has passed (dark 
square with line).  In the second kindred, a young child, the offspring of a 
consanguineous marriage, is also affected with INAD.  
 56
 
Figure 6: GCPS patient imaging.  Radiographs obtained in a 32-month old girl, 
demonstrating bilateral polysyndactyly of the great toes (a) and scoliosis of the spine (b).  
Serial axial T1 (c) and T2-weighted (d) MR images obtained in the patient at 4 years of 
age, revealing subcortical CCMs (arrows) in the right parietal and left frontal lobes as 
well as a left periventricular CCM.  Reformatted MR image (e) showing a normal central 
sulcus on the left side (arrow) and an asymmetrically formed central sulcus on the right.  
Adapted from Bilguvar et al. (74).  
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Figure 7: GCPS patient CNV and QPCR results.  Graphs depicting the results of CNV 
analysis.  On chromosome 7, a deletion was revealed within the CCM2 locus (a, 
arrowhead), but no apparent CNVs within the CCM1 locus (a, arrow).  With this analysis, 
gene deletions are represented by negative log2 ratios of the signal intensity relative to 
normal.  To be significant, the log2 ratio (y axis) must be less than 20.3. The log2 ratio at 
the CCM2 region is less than 20.5, indicating the presence of a deletion in that locus.  
There is no CNV within the CCM3 locus (b).  Bar graphs of quantitative RT-PCR of 
CCM2 (c) and GLI3 (d) showing approximately half of the relative amplification of each 
respective gene amplicon, consistent with the presence of a heterozygous deletion in the 
affected patient (2222-1) within the CNV interval.  The controls and parents (father 2222-
2 and mother 2222-3) demonstrate full amplification of each respective gene amplicon.  
Adapted from Bilguvar et al. (74).  
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Figure 8: HSP family pedigree with STS marker haplotypes.  Filled symbols show 
affected individuals, males are represented with square symbols, females with circles.  
The pattern, given the consanguinity, suggests autosomal recessive inheritance.  Below 
affected family members V1-3 and their respective parents note the haplotype as 




Figure 9: HSP cases V1 (a-c) and V3 (d-f) imaging.  Patient V1 coronal (a) and axial 
(b) T2-weighted MRI images through the thalamus and 3rd ventricle demonstrate diffuse 
enlargement of the subarachnoid spaces along the convexities likely due to gray and 
white matter loss.  Midline sagittal (c) T1-weighted MRI demonstrates the thinned corpus 
callosum.  The cerebellum, pons, and medulla appear normal.  Patient V3 coronal (d) and 
axial (e) T2-weighted MRI images through the thalamus and 3rd ventricle again 
demonstrate diffuse enlargement of the subarachnoid spaces along the convexities likely 
due to gray and white matter loss.  Midline sagittal (f) T1-weighted MRI similarly 




Figure 10: HSP family array-based SNP genotyping results.  Genotyping results using 
the GeneChip Mapping 50K XbaI Array.  Figure demonstrates multipoint linkage 
analysis plots for each chromosome.  X axis = cM distance along the chromosome.  Y 
axis = LOD score.  Results are plotted after analysis using Chunky followed by the 











Figure 11: HSP family validated linkage interval of 15q15.1-q21.3.  Graphical 
demonstration of multipoint linkage analysis demonstrating a LOD score of > 3 
(maximum: 3.6287) within a 9.8 cM region between markers rs10518676 and rs2129773 









Figure 12: HSP family whole-genome and chromosome 15-specific aCGH.  Graphical 
representation of whole-genome (a) and chromosome 15-specific (b) copy number 
variation (CNV) analysis using array-based comparative genomic hybridization (aCGH).  










Figure 13: HSP family schematic of chromosome 15 linkage results for SPG11.  X-
axis designates the distance and position along chromosome 15q in million base pairs.  
The top bar represents the linkage interval reported in this manuscript (3).  The remainder 
of the linkage intervals reported for SPG11 are shown (4-9) as are the two known 
neurological syndromes within the region (Andermann syndrome and ALS5; 1,2).   












































Table 1: Classification of diseases of cortical development. 
 
I. Malformations due to abnormal neuronal and glial proliferation or 
apoptosis 
a. Decreased proliferation / increased apoptosis or increased proliferation / 
decreased apoptosis – abnormalities of brain size 
i. Microcephaly with normal to thin cortex 
ii. Microlissencephaly (extreme microcephaly with thick cortex) 
iii. Microcephaly with extensive polymicrogyria 
iv. Macrocephalies 
b. Abnormal proliferation (abnormal cell types) 
i. Nonneoplastic 
1. Cortical hamartomas of tuberous sclerosis 
2. Cortical dysplasia with balloon cells 
3. Hemimegalencephaly 
ii. Neoplastic (associated with disordered cortex) 
1. Dysembryoplastic neuroepithelial tumor 
2. Ganglioglioma 
3. Gangliocytoma 
II. Malformations due to abnormal neuronal migration 
a. Lissencephaly / subcortical band heterotopia spectrum 
b. Cobblestone complex / congenital muscular dystrophy syndromes 
c. Heterotopia 
i. Subependymal (periventricular) 
ii. Subcortical (other than band heterotopia) 
iii. Marginal glioneuronal 
III. Malformations due to abnormal cortical organization (including late 
neuronal migration) 
a. Polymicrogyria and schizencephaly 
i. Bilateral polymicrogyria syndromes 
ii. Schizencephaly (polymicrogyria with clefts) 
iii. Polymicrogyria or schizencephaly as part of multiple congenital 
anomaly / mental retardation syndromes 
b. Cortical dysplasia without balloon cells 
c. Microdysgenesis 
IV. Malformations of cortical development, not otherwise classified 
a. Malformations secondary to inborn errors of metabolism 
i. Mictochondrial and pyruvate metabolic disorders 
ii. Peroxisomal disorders 
b. Other unclassified malformations 
i. Sublobar dysplasia 
ii. Others 
 




Table 2: Genetic basis of malformations of cortical development. 
 




Syndrome Locus Gene Protein 
Autosomal recessive periventricular 
heterotopia / micrcocephaly 8p23 MCPH1 Microcephalin 
Autosomal recessive periventricular 
heterotopia / micrcocephaly 1q31 ASPM 
Abnormal spindle-like 
microcephaly 
Autosomal recessive microcephaly 9q34 CDK5RAP2 
CDK-5 regulatory-associated 
protein 2 
Autosomal recessive microcephaly 13q12.2 CENPJ 
Centromere-associated 
protein J 
Autosomal recessive periventricular 
heterotopia / micrcocephaly 20q13.13 ARFGEF2 ARFGEF2 
Amish lethal microcephaly 17q25.3 SLC25A19 
Nuclear mitochondrial 
deoxynucleotide carrier 
Seckel syndrome 1 
3q22-
q24 ATR 
Ataxia telangiectasia and 
Rad3 related protein 
Isolated lissencephaly sequence 
Xq22.3-
q23 DCX-XLIS DCX 
Subcortical band heterotopia 
Xq22.3-
q23 DCX-XLIS DCX 
Miller-Dieker syndrome 17p13.3 
Several 
contiguous 
PAFAH1B1, 14-3-3 and 
others 
Isolated lissencephaly sequence 17p13.3 LIS1 PAFAH1B1 
Subcortical band heterotopia 17p13.3 LIS1 PAFAH1B1 
Lissencephaly with cerebellar hypoplasia 7q22 RELN Reelin 
X-linked lissencephaly with abnormal 
genitalia Xp22.13 ARX 
Aristaless-related homeobox 
protein 
Fukuyama congenital muscular dystrophy 9q31 FCMD FCMD or Fukutin 
Muscle-eye-brain disease 
1p33-
p34 POMGnT1 Unknown 
Muscle-eye-brain disease 19q13.3 FKRP Fukutin-related protein 
Congenital muscular dystrophy 19q13.3 FKRP Fukutin-related protein 
Congenital muscular dystrophy 
22q12.3-
q13.1 LARGE   
Walker-Warburg syndrome 9q34.1 POMT1 O-Mannosyl-transferase 1 
Walker-Warburg syndrome 19q13.3 FKRP Fukutin-related protein 
Walker-Warburg syndrome 9q31 FCMD FCMD 
Bilateral periventricular nodular 
heterotopia Xq28 FLNA Filamin-A 
Bilateral periventricular nodular 
heterotopia + microcephaly 20q13.3 ARFGEF2 BIG2 
Bilateral periventricular nodular 
heterotopia 5p15 Unknown Unknown 
Tuberous sclerosis chromosome 1 9q32 TSC1 Hamartin 
Tuberous sclerosis chromosome 2 16p13.3 TSC2 Tuberin 
Bilateral frontoparietal polymicrogyria 16q13 GPR56 Unknown 
Warburg microsyndrome 1 2q21.3 RAB3GAP   
Bilateral perisylvian polymicrogyria Xq28 Unknown Unknown 
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10,000 167 (families) 




10,000 157 (families) 
Homozygosity mapping in 
erythrokeratodermia 
variabilis 
BeadArray 4,700 20 





Copy-number and allelic 




Linkage and association 
study of systemic lupus 
erythematosus 
SNPstream 45 1,915 
Association study of HDL-
cholesterol levels 
GeneChip 7,300 6 
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Table 4: Quantitative PCR results showing deletions in CCM2 and GLI3 as well as 
several intervening genes. 
 
Gene Start base pair End base pair Exon Result 
CDC2L5 39763349 39908385 13 normal 
INHBA 41501843 41515946 2 normal 
GLI3 41776920 42036135 2 deletion 
GLI3 41776920 42036135 12 deletion 
HECW1 43124602 43376178 8 deletion 
CAMK2B 44032137 44138464 19 deletion 
NPCL1 44325377 44354154 11 deletion 
CCM2 44813092 44889290 4 deletion 
CCM2 44813092 44889290 9 deletion 
IGFBP1 45701194 45706506 2 normal 
TBRG4 44912940 44924557 2 normal 
ADCY1 45387361 45535952 13 normal 
IGFBP3 45725089 45734111 2 normal 
Adapted from Bilguvar et al. (74). 
 
 
 
 
 
 
 
 
 
 
 
